Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Trametinib & Melanoma (cutaneous) (BRAF m), in a significant development, the FDA granted approval for trametinib to be used as a standalone treatment for patients with unresectable or metastatic Melanoma (cutaneous) (BRAF m). This decision was informed by data on progression-free survival and overall survival obtained from the METRIC trial, with the mutations being identified through an FDA-approved test (1, 2).
Trametinib is authorized by the EMA for use as a monotherapy in adults who have unresectable or metastatic Melanoma (cutaneous…